Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off

Multiple First-In-Class Pipeline Assets

 
• By Xu Hu
  
Bispecific AB
Alphamab Oncology's CEO talks about the firm's late-stage anti-HER2 bispecific antibody and ADC and rationales of developing the first-in-class ADCs. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Interviews

More from China